Search
Sign In
Sign In
Sources
11 Total Sources
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
Left
17%
Center
50%
Right
33%
All
11
Left
1
Center
3
Right
2
Others
5
Yahoo Finance
10d ago
AbCellera's ABCL-635 Reduces Menopause Hot Flashes by 83% in Phase II Trial
Reuters
10d ago
AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge | Reuters
Barron's
10d ago
AbCellera Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News. - Barron's
BNN Bloomberg
11d ago
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
Contemporary Obgyn
10d ago
Phase 2 data: ABCL635 reduces frequency, severity of VMS symptoms | Contemporary OB/GYN
ibtimes.com.au
10d ago
AbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results
MarketBeat
10d ago
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
Business Wire
10d ago
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
investors.abcellera.com
10d ago
AbCellera Biologics Inc. - AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
The Globe and Mail
10d ago
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - The Globe and Mail
Patient Care Online
10d ago
ABCL635 Reduced Vasomotor Symptom Frequency and Severity in Phase 2 Trial | Patient Care Online